Angion’s lead organ damage drug took two strikes earlier this year, flopping as a repurposed effort for Covid-19 and whiffing in high-risk kidney transplant patients. The biotech reported a third on Thursday, raising serious questions about the program’s future.
In a Phase II study looking at some cardiac surgery patients at risk of kidney injury, Angion reported its ANG-3777 candidate missed badly on the primary endpoint. The results come about a month and a half after the kidney transplant study and less than five months after the Covid-19 trial, ostensibly leaving the candidate on the chopping block.
$ANGN shares were down about 18% after the bell Thursday evening and into early Friday morning. During a Thursday afternoon investor call, CEO Jay Venkatesan implied this could be end of the road for ANG-3777, saying Angion’s ‘primary focus’ moving forward will be its Phase II tyrosine kinase receptor inhibitor, ANG-3070. But Angion and its partner Vifor Pharma will need to further review the data, he said, noting a decision will likely be made sometime in early 2022 about next steps.
Much of Angion’s focus post-reveal dealt with a secondary endpoint that also missed statistical significance, but one which the company said is more commonly used as a regulatory benchmark. In damage control mode on the investor call, Venkatesan stressed this point and noted Angion still wants to take a closer look at the data.
‘We have been clear with investors that this trial was not intended to generate statistically significant results, particularly on the [secondary] MAKE90 endpoint, where we believe we were not sufficiently powered,’ Venkatesan said.
The chief added there was a ‘potential meaningful’ benefit here and would likely be the primary endpoint in a pivotal Phase III study, should Angion elect to move forward.
For Thursday’s primary, researchers measured the percentage increase in serum creatinine based upon area under the curve, starting at 24 hours after patients’ surgery through day 6. ANG-3777 induced an 8.4% increase while placebo patients saw a 7.3% increase, amounting to a miserable p-value of p=0.77.
Angion then looked at MAKE90 events between the two groups, an endpoint observing how many patients suffer death, initiation of renal replacement therapy or a greater than 25% decline in eGFR within 90 days of their surgery. Fewer patients in the drug arm saw such events at 14.7%, compared to 21.5% on placebo, good for a p-value of p=0.155.
Despite this being a statistically insignificant result, Venkatesan described this as an ‘encouraging’ result.
The only endpoint that reached statistical significance in this trial was another secondary measure in which fewer ANG-3777 patients saw a greater than 25% decrease in eGFR after three months versus placebo.
ANG-3777’s fate comes after the two earlier misses this year. The candidate missed the primary and secondary endpoints in a Phase II study in severe Covid-19 patients at risk for ARDS and failed to beat out placebo in improving eGFR in patients who had received a deceased donor kidney transplant at risk of developing delayed graft function.
https://endpts.com/snakebit-angion-reports-another-miss-for-lead-program-as-biotech-prepares-to-shift-its-primary-focus/